VolitionRx Statistics

Total Valuation

VolitionRx has a market cap or net worth of $10.66 million. The enterprise value is $19.26 million.

Market Cap	10.66M
Enterprise Value	19.26M

Important Dates

The next estimated earnings date is Thursday, August 13, 2026, after market close.

Earnings Date	Aug 13, 2026
Ex-Dividend Date	n/a

Share Statistics

VolitionRx has 8.33 million shares outstanding. The number of shares has increased by 29.87% in one year.

Current Share Class	8.33M
Shares Outstanding	8.33M
Shares Change (YoY)	+29.87%
Shares Change (QoQ)	+13.78%
Owned by Insiders (%)	5.07%
Owned by Institutions (%)	17.53%
Float	6.66M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	4.32
Forward PS	4.42
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	7.81
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 0.33

Current Ratio	0.33
Quick Ratio	0.25
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-7.26

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-153.54%
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	475.97%
Weighted Average Cost of Capital (WACC)	15.24%
Revenue Per Employee	$36,807
Profits Per Employee	-$367,135
Employee Count	67
Asset Turnover	0.28
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -91.58% in the last 52 weeks. The beta is 1.04, so VolitionRx's price volatility has been similar to the market average.

Beta (5Y)	1.04
52-Week Price Change	-91.58%
50-Day Moving Average	2.25
200-Day Moving Average	5.57
Relative Strength Index (RSI)	31.55
Average Volume (20 Days)	361,857

Short Selling Information

The latest short interest is 389,005, so 4.67% of the outstanding shares have been sold short.

Short Interest	389,005
Short Previous Month	269,068
Short % of Shares Out	4.67%
Short % of Float	5.84%
Short Ratio (days to cover)	1.28

Income Statement

In the last 12 months, VolitionRx had revenue of $2.47 million and -$24.60 million in losses. Loss per share was -$4.20.

Revenue	2.47M
Gross Profit	2.47M
Operating Income	-21.57M
Pretax Income	-24.73M
Net Income	-24.60M
EBITDA	-20.63M
EBIT	-21.57M
Loss Per Share	-$4.20

Full Income Statement

Balance Sheet

The company has $3.10 million in cash and $11.70 million in debt, giving a net cash position of -$8.60 million or -$1.03 per share.

Cash & Cash Equivalents	3.10M
Total Debt	11.70M
Net Cash	-8.60M
Net Cash Per Share	-$1.03
Equity (Book Value)	-33.36M
Book Value Per Share	-4.03
Working Capital	-9.05M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$20.67 million and capital expenditures -$96,964, giving a free cash flow of -$20.76 million.

Operating Cash Flow	-20.67M
Capital Expenditures	-96,964
Depreciation & Amortization	939,136
Net Borrowing	7.17M
Free Cash Flow	-20.76M
FCF Per Share	-$2.49

Full Cash Flow Statement

Margins

Gross Margin	100.00%
Operating Margin	-874.50%
Pretax Margin	-1,002.82%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

VolitionRx does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-29.87%
Shareholder Yield	-29.87%
Earnings Yield	-230.69%
FCF Yield	-194.72%

Analyst Forecast

The average price target for VolitionRx is $16.97, which is 1,225.78% higher than the current price. The consensus rating is "Buy".

Price Target	$16.97
Price Target Difference	1,225.78%
Analyst Consensus	Buy
Analyst Count	5
Revenue Growth Forecast (3Y)	132.80%
EPS Growth Forecast (3Y)	n/a

Stock Forecasts

Stock Splits

The last stock split was on April 28, 2026. It was a reverse split with a ratio of 1:20.

Last Split Date	Apr 28, 2026
Split Type	Reverse
Split Ratio	1:20

Scores

VolitionRx has an Altman Z-Score of -48.3 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-48.3
Piotroski F-Score	2